Aaron N.A. Verty

1.1k total citations
19 papers, 905 citations indexed

About

Aaron N.A. Verty is a scholar working on Pharmacology, Endocrine and Autonomic Systems and Cognitive Neuroscience. According to data from OpenAlex, Aaron N.A. Verty has authored 19 papers receiving a total of 905 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pharmacology, 11 papers in Endocrine and Autonomic Systems and 6 papers in Cognitive Neuroscience. Recurrent topics in Aaron N.A. Verty's work include Cannabis and Cannabinoid Research (14 papers), Regulation of Appetite and Obesity (9 papers) and Sleep and Wakefulness Research (6 papers). Aaron N.A. Verty is often cited by papers focused on Cannabis and Cannabinoid Research (14 papers), Regulation of Appetite and Obesity (9 papers) and Sleep and Wakefulness Research (6 papers). Aaron N.A. Verty collaborates with scholars based in Australia and Canada. Aaron N.A. Verty's co-authors include Iain S. McGregor, Paul E. Mallet, Brian J. Oldfield, Andrew M. Allen, Aneta Stefanidis, James R. McFarlane, Andrew J. McAinch, Deanne H. Hryciw, Neil C. Owens and Michael A. Cowley and has published in prestigious journals such as PLoS ONE, Brain Research and Endocrinology.

In The Last Decade

Aaron N.A. Verty

19 papers receiving 883 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aaron N.A. Verty Australia 16 552 332 308 295 236 19 905
Belén Ferrer Spain 8 781 1.4× 165 0.5× 514 1.7× 139 0.5× 179 0.8× 10 938
Galina Burdyga United Kingdom 12 257 0.5× 571 1.7× 182 0.6× 325 1.1× 146 0.6× 14 932
Floortje Remmers Germany 15 611 1.1× 150 0.5× 457 1.5× 146 0.5× 191 0.8× 20 998
Miguel Navarro Spain 14 1.4k 2.6× 253 0.8× 1.0k 3.3× 190 0.6× 338 1.4× 17 1.7k
Marja D. Van Sickle Canada 8 1.5k 2.7× 264 0.8× 771 2.5× 232 0.8× 429 1.8× 10 1.7k
Benedetta Canestrelli Italy 10 258 0.5× 259 0.8× 156 0.5× 199 0.7× 72 0.3× 10 681
Ida Fredriksson United States 15 201 0.4× 162 0.5× 565 1.8× 205 0.7× 154 0.7× 22 878
Andreas Artmann Denmark 10 537 1.0× 100 0.3× 218 0.7× 153 0.5× 80 0.3× 12 757
Kara L. Stuhr United States 11 618 1.1× 179 0.5× 255 0.8× 148 0.5× 199 0.8× 12 812
Pauline Lafenêtre France 12 518 0.9× 91 0.3× 450 1.5× 125 0.4× 207 0.9× 17 851

Countries citing papers authored by Aaron N.A. Verty

Since Specialization
Citations

This map shows the geographic impact of Aaron N.A. Verty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aaron N.A. Verty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aaron N.A. Verty more than expected).

Fields of papers citing papers by Aaron N.A. Verty

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aaron N.A. Verty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aaron N.A. Verty. The network helps show where Aaron N.A. Verty may publish in the future.

Co-authorship network of co-authors of Aaron N.A. Verty

This figure shows the co-authorship network connecting the top 25 collaborators of Aaron N.A. Verty. A scholar is included among the top collaborators of Aaron N.A. Verty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aaron N.A. Verty. Aaron N.A. Verty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Verty, Aaron N.A., Aneta Stefanidis, Andrew J. McAinch, Deanne H. Hryciw, & Brian J. Oldfield. (2015). Anti-Obesity Effect of the CB2 Receptor Agonist JWH-015 in Diet-Induced Obese Mice. PLoS ONE. 10(11). e0140592–e0140592. 83 indexed citations
2.
Jenkin, Kayte A., Aaron N.A. Verty, Andrew J. McAinch, & Deanne H. Hryciw. (2012). Endocannabinoids and the renal proximal tubule: An emerging role in diabetic nephropathy. The International Journal of Biochemistry & Cell Biology. 44(11). 2028–2031. 24 indexed citations
3.
Verty, Aaron N.A., Sarah H. Lockie, Aneta Stefanidis, & Brian J. Oldfield. (2012). Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice. International Journal of Obesity. 37(2). 279–287. 25 indexed citations
4.
Verty, Aaron N.A., et al.. (2011). The Cannabinoid Receptor Agonist THC Attenuates Weight Loss in a Rodent Model of Activity-Based Anorexia. Neuropsychopharmacology. 36(7). 1349–1358. 58 indexed citations
5.
Verty, Aaron N.A. & Brian J. Oldfield. (2011). Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin concentrating hormone antagonist SNAP-94847 in diet induced obese mice. Obesity Research & Clinical Practice. 5. 62–62. 2 indexed citations
6.
Verty, Aaron N.A., Andrew M. Allen, & Brian J. Oldfield. (2010). The Endogenous Actions of Hypothalamic Peptides on Brown Adipose Tissue Thermogenesis in the Rat. Endocrinology. 151(9). 4236–4246. 51 indexed citations
7.
Verty, Aaron N.A., Wee‐Ming Boon, Paul E. Mallet, Iain S. McGregor, & Brian J. Oldfield. (2009). Involvement of hypothalamic peptides in the anorectic action of the CB1 receptor antagonist rimonabant (SR 141716). European Journal of Neuroscience. 29(11). 2207–2216. 28 indexed citations
8.
Verty, Aaron N.A., Andrew M. Allen, & Brian J. Oldfield. (2008). The Effects of Rimonabant on Brown Adipose Tissue in Rat: Implications for Energy Expenditure. Obesity. 17(2). 254–261. 85 indexed citations
9.
Stefanidis, Aneta, Aaron N.A. Verty, Andrew M. Allen, et al.. (2008). The Role of Thermogenesis in Antipsychotic Drug‐induced Weight Gain. Obesity. 17(1). 16–24. 91 indexed citations
10.
Verty, Aaron N.A. & Brian J. Oldfield. (2007). The effect of the cannabinoid receptor antagonist, rimonabant (SR 141716) on energy expenditure.. Appetite. 49(1). 337–337. 1 indexed citations
11.
Verty, Aaron N.A., Wee‐Ming Boon, & Brian J. Oldfield. (2007). The impact of CB1 cannabinoid receptor antagonist SR 141716 (rimonabant) on hypothalamic peptides mediating energy balance.. Appetite. 49(1). 337–337. 1 indexed citations
12.
Verty, Aaron N.A., Iain S. McGregor, & Paul E. Mallet. (2005). Paraventricular hypothalamic CB1 cannabinoid receptors are involved in the feeding stimulatory effects of Δ9-tetrahydrocannabinol. Neuropharmacology. 49(8). 1101–1109. 60 indexed citations
13.
Verty, Aaron N.A., et al.. (2004). Modulation of morphine-induced Fos-immunoreactivity by the cannabinoid receptor antagonist SR 141716. Neuropharmacology. 47(8). 1157–1169. 38 indexed citations
14.
Verty, Aaron N.A., Iain S. McGregor, & Paul E. Mallet. (2004). The dopamine receptor antagonist SCH 23390 attenuates feeding induced by Δ9-tetrahydrocannabinol. Brain Research. 1020(1-2). 188–195. 40 indexed citations
15.
Verty, Aaron N.A., James R. McFarlane, Iain S. McGregor, & Paul E. Mallet. (2004). Evidence for an interaction between CB1 cannabinoid and oxytocin receptors in food and water intake. Neuropharmacology. 47(4). 593–603. 49 indexed citations
16.
Verty, Aaron N.A., et al.. (2004). A cannabinoid receptor antagonist attenuates conditioned place preference but not behavioural sensitization to morphine. Brain Research. 1026(2). 244–253. 66 indexed citations
17.
Verty, Aaron N.A., James R. McFarlane, Iain S. McGregor, & Paul E. Mallet. (2004). Evidence for an Interaction between CB1 Cannabinoid and Melanocortin MCR-4 Receptors in Regulating Food Intake. Endocrinology. 145(7). 3224–3231. 83 indexed citations
18.
19.
Mallet, Paul E., et al.. (2003). The cannabinoid receptor antagonist SR�141716 attenuates overfeeding induced by systemic or intracranial morphine. Psychopharmacology. 168(3). 314–323. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Belén Ferrer Breakdown of academic impact, for papers by Galina Burdyga Breakdown of academic impact, for papers by Floortje Remmers Breakdown of academic impact, for papers by Miguel Navarro Breakdown of academic impact, for papers by Marja D. Van Sickle Breakdown of academic impact, for papers by Benedetta Canestrelli Breakdown of academic impact, for papers by Ida Fredriksson Breakdown of academic impact, for papers by Andreas Artmann Breakdown of academic impact, for papers by Kara L. Stuhr Breakdown of academic impact, for papers by Pauline Lafenêtre
Rankless by CCL
2026